RxDoctor Payments Data

Nkeiruka Okoye, MD

Hematology & Oncology · Middletown, OHNPI 1437364387

Payments from drug & device makers

$15,686in general payments, 2019–2025

Across 539 payments — averaging $29.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacyclics LLC, An Abbvie Company$6K
  • Novartis$904
  • Johnson & Johnson$675
  • Merck$651
  • AbbVie$547
  • Pfizer$526
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,36894%
  • Education$5486%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pharmacyclics LLC, An Abbvie Company43$6,163
Novartis52$904
Johnson & Johnson(2 entities)27$675
Merck31$651
AbbVie21$547
Pfizer35$526
Gilead(2 entities)24$475
Eisai Inc.16$382
AstraZeneca(2 entities)19$380
Incyte Corporation15$301
Lilly USA, LLC20$299
Daiichi Sankyo Inc.16$293
Bayer14$289
E.r. Squibb & Sons, L.L.C.18$278
GSK14$260
Regeneron Healthcare Solutions, Inc.13$239
Genentech USA, Inc.14$237
AVEO Pharmaceuticals, Inc.5$183
Genmab U.S., Inc.7$178
Bristol Myers Squibb10$167
Amgen9$155
Sanofi8$142
Array Biopharma Inc9$140
Stemline Therapeutics Inc.6$113
Rigel Pharmaceuticals, Inc.8$112
Takeda Pharmaceuticals U.S.A., Inc.7$106
Boehringer Ingelheim5$96
EMD Serono, Inc.4$82
Seagen Inc.3$78
Beigene USA, Inc.3$75
Tersera Therapeutics LLC4$74
Pharmaessentia USA Corporation3$71
Ipsen Biopharmaceuticals, Inc3$61
Astellas Pharma US Inc4$60
Sobi, Inc3$58
Taiho Oncology, Inc.3$58
Puma Biotechnology, Inc.4$56
Foundation Medicine, Inc.2$56
Adaptive Biotechnologies Corporation3$55
Jazz Pharmaceuticals Inc.2$49
Kyowa Kirin, Inc.3$47
Clovis Oncology, Inc.3$42
Deciphera Pharmaceuticals Inc.3$41
ADC Therapeutics America, Inc.2$40
Beone Medicines USA, Inc.2$39
Syndax Pharmaceuticals, Inc.2$38
Exelixis Inc.2$36
Blueprint Medicines Corporation2$33
Agios Pharmaceuticals, Inc.2$31
Karyopharm Therapeutics Inc.1$27
Immunocore Limited1$24
Caris MPI, Inc.1$23
Servier Pharmaceuticals LLC1$22
Morphosys, US Inc.1$21
Mirati Therapeutics, Inc.1$19
Heron Therapeutics, Inc.1$18
Alnylam Pharmaceuticals Inc.1$17
CTI Biopharma Corp.1$16
Mylan Institutional Inc.1$14
Sumitomo Pharma America, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,686 in reported general payments places this provider in the 60th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,379,543
Medicare patients
466
Services billed
101,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib55$843,586
ImbruvicaIbrutinib48$777,764
CalquenceAcalabrutinib Maleate39$604,860
PomalystPomalidomide22$504,636
LenvimaLenvatinib Mesylate20$490,040
Lenalidomide21$368,023
XtandiEnzalutamide30$334,341
EliquisApixaban57$60,321
XareltoRivaroxaban34$48,425
Abiraterone Acetate29$27,302
VeozahFezolinetant14$10,812
Anastrozole153$2,632
Oxycodone Hcl31$1,823
Gabapentin112$1,658
Dexamethasone45$1,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$526$903,907112 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$6,163$777,76448 claims
AstraZenecaCalquence$380$604,86039 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$278$504,63622 claims
Eisai Inc.Lenvima$382$490,04020 claims
Astellas Pharma US IncXtandi, Veozah$60$345,15344 claims
Johnson & JohnsonXarelto$675$48,42534 claims
Lilly USA, LLCOlanzapine$299$22314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Middletown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →